FR13C0044I2 - Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine - Google Patents

Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine

Info

Publication number: FR13C0044I2
Authority: FR; France
Prior art keywords: dihydroimidazolones; treatment; canine epilepsy; canine; epilepsy
Prior art date: 2002-10-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR13C0044C

Other languages

English (en)

French (fr)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim Vetmedica Gm

Original Assignee

Boehringer Ingelheim Vetmedica Gm

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-10

Filing date

2013-07-24

Publication date

2014-03-07

2013-07-24 Application filed by Boehringer Ingelheim Vetmedica Gm filed Critical Boehringer Ingelheim Vetmedica Gm

2013-08-30 Publication of FR13C0044I1 publication Critical patent/FR13C0044I1/fr

2014-03-07 Application granted granted Critical

2014-03-07 Publication of FR13C0044I2 publication Critical patent/FR13C0044I2/fr

Status Active legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Virology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

FR13C0044C 2002-10-10 2013-07-24 Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine Active FR13C0044I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41759002P	2002-10-10	2002-10-10
PCT/EP2003/011212 WO2004032938A1 (en)	2002-10-10	2003-10-09	Use of dihydroimidazolones for the treatment of epilepsy in dogs

Publications (2)

Publication Number	Publication Date
FR13C0044I1 FR13C0044I1 (ja)	2013-08-30
FR13C0044I2 true FR13C0044I2 (fr)	2014-03-07

Family

ID=32094042

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR13C0044C Active FR13C0044I2 (fr)	2002-10-10	2013-07-24	Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
FR22C1033C Active FR22C1033I1 (fr)	2002-10-10	2022-06-30	Utilisation de dihydroimidazolones pour le traitement des chiens

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
FR22C1033C Active FR22C1033I1 (fr)	2002-10-10	2022-06-30	Utilisation de dihydroimidazolones pour le traitement des chiens

Country Status (28)

Country	Link
US (5)	US20050070537A1 (ja)
EP (3)	EP2845594B1 (ja)
JP (4)	JP4694202B2 (ja)
KR (2)	KR20110063843A (ja)
CN (2)	CN1726040B (ja)
AR (1)	AR041573A1 (ja)
AT (1)	ATE418337T1 (ja)
AU (2)	AU2003273978B2 (ja)
BE (1)	BE2013C046I2 (ja)
BR (1)	BR0315225A (ja)
CA (2)	CA2501772C (ja)
CY (3)	CY1109961T1 (ja)
DE (1)	DE60325496D1 (ja)
DK (2)	DK2845594T3 (ja)
ES (2)	ES2316808T3 (ja)
FR (2)	FR13C0044I2 (ja)
HK (1)	HK1085920A1 (ja)
HR (3)	HRP20090667B1 (ja)
HU (2)	HUS1300035I1 (ja)
LU (1)	LU92238I2 (ja)
MX (1)	MXPA05003663A (ja)
NZ (1)	NZ539864A (ja)
PL (2)	PL238776B1 (ja)
PT (2)	PT1553952E (ja)
SI (2)	SI1553952T1 (ja)
TW (2)	TWI424849B (ja)
WO (1)	WO2004032938A1 (ja)
ZA (1)	ZA200502245B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050070537A1 (en) *	2002-10-10	2005-03-31	Chris Rundfeldt	Use of dihydroimidazolones for the treatment of dogs
AU2004255414A1 (en) *	2003-07-11	2005-01-20	Boehringer Ingelheim Vetmedica Gmbh	Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
RU2014109079A (ru)	2011-08-12	2015-09-20	Бёрингер Ингельхайм Ветмедика Гмбх	Фармацевтическая композиция с маскированным вкусом
JP6193613B2 (ja) *	2013-05-10	2017-09-06	学校法人麻布獣医学園	てんかん発作のモニタリングシステム及びモニタリング方法
US9820988B2 (en)	2014-03-24	2017-11-21	Boehringer Ingelheim Vetmedica Gmbh	Treatment of epileptic disorders in feline animals
EP3150598B1 (en)	2014-05-28	2019-02-13	TOA Eiyo Ltd.	Substituted tropane derivatives
US10117891B2 (en)	2014-09-16	2018-11-06	India Globalization Capital, Inc.	Cannabinoid composition for treating pain
EP3247359A4 (en)	2015-01-25	2018-08-08	India Globalization Capital, Inc.	Composition and method for treating seizure disorders
WO2017027651A1 (en)	2015-08-12	2017-02-16	India Globalization Capital, Inc.	Method and composition for treating cachexia and eating disorders
EP3471746A4 (en)	2016-06-15	2020-02-26	India Globalization Capital, Inc.	METHOD AND COMPOSITION FOR TREATING EPILEPTIC DISORDERS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4044021A (en)	1971-10-21	1977-08-23	American Cyanamid Company	Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en)	1975-02-07	1976-01-13	Morton-Norwich Products, Inc.	1-Arylmethyl-2-imidazolidinones
DE19532668A1 (de)	1995-09-05	1997-03-06	Dresden Arzneimittel	Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
US5869481A (en) *	1995-09-05	1999-02-09	Arzneitmittelwerk Dresden G.M.B.H.	Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19721580A1 (de) *	1997-05-23	1998-11-26	Dresden Arzneimittel	Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
WO1999000346A1 (en)	1997-06-26	1999-01-07	Board Of Regents, The University Of Texas System	Synthesis of dihydrohonokiol compositions
JP4669095B2 (ja)	1999-07-19	2011-04-13	太陽化学株式会社	ペットの問題行動抑制組成物
ATE540943T1 (de)	2002-03-07	2012-01-15	Boehringer Ingelheim Pharma	3-ä(2-ää4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoümethylü-1-methyl-1h-benzimidazol-5- carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester methansulfonat
US20050070537A1 (en) *	2002-10-10	2005-03-31	Chris Rundfeldt	Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (de)	2003-08-29	2005-03-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
RU2014109079A (ru)	2011-08-12	2015-09-20	Бёрингер Ингельхайм Ветмедика Гмбх	Фармацевтическая композиция с маскированным вкусом
US9820988B2 (en)	2014-03-24	2017-11-21	Boehringer Ingelheim Vetmedica Gmbh	Treatment of epileptic disorders in feline animals

2003
- 2003-10-06 US US10/680,459 patent/US20050070537A1/en not_active Abandoned
- 2003-10-08 TW TW098142077A patent/TWI424849B/zh not_active IP Right Cessation
- 2003-10-08 TW TW092127976A patent/TWI324067B/zh not_active IP Right Cessation
- 2003-10-09 PT PT03757945T patent/PT1553952E/pt unknown
- 2003-10-09 DK DK14191084.4T patent/DK2845594T3/da active
- 2003-10-09 SI SI200331504T patent/SI1553952T1/sl unknown
- 2003-10-09 PL PL397320A patent/PL238776B1/pl unknown
- 2003-10-09 ES ES03757945T patent/ES2316808T3/es not_active Expired - Lifetime
- 2003-10-09 AR ARP030103685A patent/AR041573A1/es unknown
- 2003-10-09 HR HRP20090667AA patent/HRP20090667B1/hr not_active IP Right Cessation
- 2003-10-09 KR KR1020117009632A patent/KR20110063843A/ko not_active Application Discontinuation
- 2003-10-09 KR KR1020057006150A patent/KR101110587B1/ko active Protection Beyond IP Right Term
- 2003-10-09 PL PL374603A patent/PL214702B1/pl unknown
- 2003-10-09 BR BR0315225-1A patent/BR0315225A/pt active Pending
- 2003-10-09 EP EP14191084.4A patent/EP2845594B1/en not_active Expired - Lifetime
- 2003-10-09 MX MXPA05003663A patent/MXPA05003663A/es active IP Right Grant
- 2003-10-09 JP JP2004542480A patent/JP4694202B2/ja not_active Expired - Lifetime
- 2003-10-09 ES ES14191084T patent/ES2908453T3/es not_active Expired - Lifetime
- 2003-10-09 EP EP08167818A patent/EP2036563A1/en not_active Ceased
- 2003-10-09 SI SI200332622T patent/SI2845594T1/sl unknown
- 2003-10-09 DK DK03757945T patent/DK1553952T3/da active
- 2003-10-09 DE DE60325496T patent/DE60325496D1/de not_active Expired - Lifetime
- 2003-10-09 CN CN2003801057558A patent/CN1726040B/zh not_active Expired - Lifetime
- 2003-10-09 AU AU2003273978A patent/AU2003273978B2/en not_active Expired
- 2003-10-09 EP EP03757945A patent/EP1553952B1/en not_active Expired - Lifetime
- 2003-10-09 AT AT03757945T patent/ATE418337T1/de active
- 2003-10-09 CA CA2501772A patent/CA2501772C/en not_active Expired - Lifetime
- 2003-10-09 CN CN2010101440231A patent/CN101890019A/zh active Pending
- 2003-10-09 WO PCT/EP2003/011212 patent/WO2004032938A1/en active Application Filing
- 2003-10-09 PT PT141910844T patent/PT2845594T/pt unknown
- 2003-10-09 NZ NZ539864A patent/NZ539864A/en not_active IP Right Cessation
- 2003-10-09 CA CA2727722A patent/CA2727722C/en not_active Expired - Lifetime
2005
- 2005-03-17 ZA ZA2005/02245A patent/ZA200502245B/en unknown
- 2005-04-08 HR HRP20050322AA patent/HRP20050322B1/hr not_active IP Right Cessation
2006
- 2006-05-23 HK HK06105907.5A patent/HK1085920A1/xx not_active IP Right Cessation
2007
- 2007-07-18 US US11/879,708 patent/US8859540B2/en active Active
2009
- 2009-03-20 CY CY20091100314T patent/CY1109961T1/el unknown
- 2009-10-12 AU AU2009225322A patent/AU2009225322A1/en not_active Abandoned
2010
- 2010-12-28 JP JP2010293113A patent/JP2011068685A/ja not_active Withdrawn
2012
- 2012-09-14 US US13/616,440 patent/US8962617B2/en not_active Expired - Lifetime
2013
- 2013-07-03 LU LU92238C patent/LU92238I2/fr unknown
- 2013-07-03 BE BE2013C046C patent/BE2013C046I2/fr unknown
- 2013-07-11 CY CY2013031C patent/CY2013031I2/el unknown
- 2013-07-24 FR FR13C0044C patent/FR13C0044I2/fr active Active
- 2013-07-24 HU HUS1300035C patent/HUS1300035I1/hu unknown
2014
- 2014-02-14 JP JP2014026704A patent/JP6249812B2/ja not_active Expired - Lifetime
- 2014-11-17 US US14/542,888 patent/US9469611B2/en not_active Expired - Lifetime
2016
- 2016-02-29 JP JP2016038151A patent/JP2016104817A/ja not_active Withdrawn
- 2016-08-30 US US15/251,022 patent/US20160367562A1/en not_active Abandoned
2020
- 2020-02-07 HR HRP20200207AA patent/HRP20200207A2/hr not_active Application Discontinuation
2022
- 2022-03-31 CY CY20221100250T patent/CY1125103T1/el unknown
- 2022-06-30 FR FR22C1033C patent/FR22C1033I1/fr active Active
- 2022-07-28 HU HUS2200036C patent/HUS2200036I1/hu unknown

Also Published As

Publication number	Publication date
US20050070537A1 (en)	2005-03-31
DK1553952T3 (da)	2009-04-20
KR101110587B1 (ko)	2012-02-15
JP6249812B2 (ja)	2017-12-20
US8962617B2 (en)	2015-02-24
PL214702B1 (pl)	2013-09-30
SI1553952T1 (sl)	2009-04-30
JP2016104817A (ja)	2016-06-09
CY1125103T1 (el)	2023-01-05
EP1553952A1 (en)	2005-07-20
ES2316808T3 (es)	2009-04-16
FR22C1033I1 (fr)	2022-09-09
AR041573A1 (es)	2005-05-18
US8859540B2 (en)	2014-10-14
BR0315225A (pt)	2005-08-23
HRP20090667A2 (hr)	2010-07-31
US20150072983A1 (en)	2015-03-12
JP2011068685A (ja)	2011-04-07
DK2845594T3 (da)	2022-03-07
ZA200502245B (en)	2005-11-30
LU92238I2 (fr)	2013-09-03
CN101890019A (zh)	2010-11-24
HK1085920A1 (en)	2006-09-08
SI2845594T1 (sl)	2022-04-29
US20160367562A1 (en)	2016-12-22
HRP20200207A2 (hr)	2020-07-24
ATE418337T1 (de)	2009-01-15
EP2036563A1 (en)	2009-03-18
US20130065898A1 (en)	2013-03-14
CA2727722A1 (en)	2004-04-22
EP1553952B1 (en)	2008-12-24
AU2003273978A1 (en)	2004-05-04
KR20110063843A (ko)	2011-06-14
TW201010706A (en)	2010-03-16
HRP20050322A2 (en)	2006-05-31
TWI424849B (zh)	2014-02-01
MXPA05003663A (es)	2005-06-08
HUS1300035I1 (hu)	2017-10-30
HUS2200036I1 (hu)	2022-08-28
PT2845594T (pt)	2022-03-09
LU92238I9 (ja)	2019-01-09
PT1553952E (pt)	2009-02-10
TWI324067B (en)	2010-05-01
CY2013031I1 (el)	2015-11-04
CN1726040A (zh)	2006-01-25
BE2013C046I2 (ja)	2022-08-09
WO2004032938A1 (en)	2004-04-22
DE60325496D1 (de)	2009-02-05
JP2006503873A (ja)	2006-02-02
NZ539864A (en)	2007-11-30
CA2727722C (en)	2013-05-28
PL397320A1 (pl)	2012-02-13
US9469611B2 (en)	2016-10-18
AU2003273978B2 (en)	2009-07-23
JP2014080449A (ja)	2014-05-08
JP4694202B2 (ja)	2011-06-08
CY1109961T1 (el)	2014-09-10
US20080027057A1 (en)	2008-01-31
FR13C0044I1 (ja)	2013-08-30
AU2009225322A1 (en)	2009-11-05
CA2501772C (en)	2011-08-23
PL374603A1 (en)	2005-10-31
TW200503726A (en)	2005-02-01
HRP20050322B1 (hr)	2013-12-06
EP2845594A1 (en)	2015-03-11
CN1726040B (zh)	2010-05-12
EP2845594B1 (en)	2022-02-23
PL238776B1 (pl)	2021-10-04
KR20050056237A (ko)	2005-06-14
HRP20090667B1 (hr)	2021-06-11
ES2908453T3 (es)	2022-04-29
CA2501772A1 (en)	2004-04-22
CY2013031I2 (el)	2015-11-04

Publication	Publication Date	Title
FR13C0044I2 (fr)	2014-03-07	Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
FR2854074B1 (fr)	2007-11-23	Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
FR13C0030I1 (fr)	2013-07-05	Compositions pour le traitement de troubles gastrointestinaux
FR13C0060I2 (fr)	2014-04-11	Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
FR2846870B1 (fr)	2005-07-01	Materiel d'osteosynthese pour le traitement d'un cubitus"long"
FR2840804B1 (fr)	2004-09-17	Systeme pour le traitement de l'obesite et implant pour un tel systeme
CH1143977H1 (fr)	2007-02-15	2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
MA27395A1 (fr)	2005-06-01	Utilisation de prebiotiques pour le traitement et la prevention des syndromes hyper-glycemiques
DZ3014A1 (fr)	2004-03-27	Médicaments pour le traitement de l'hypertension.
NO20033804L (no)	2003-09-30	Karbamatforbindelser for behandling av smerte
FR2860154B1 (fr)	2006-02-03	Composition pour le traitement de la mauvaise haleine
FR2835851B1 (fr)	2004-04-23	Composition pour le traitement d'alliages de magnesium
MA25852A1 (fr)	2003-07-01	Methode pour le traitement de l'inflammation.
MA26117A1 (fr)	2004-04-01	Nouveau compose pour le traitement de l'impuissance
FR2800614B1 (fr)	2002-01-04	Composition pour le traitement des infections des voies respiratoires
DE60005685D1 (de)	2003-11-06	Oxazinocarbazole zur behandlung von cns-erkrankungen
FR2834887B1 (fr)	2007-06-15	Utilisation d'un extrait d'artemia pour le traitement des peaux agees
DE60133596D1 (de)	2008-05-21	S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie
FR2844815B3 (fr)	2004-07-30	Couvercle de surete pour bouches d'egouts
FR2849599B1 (fr)	2006-12-29	Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR2843015B1 (fr)	2005-06-10	Implant pour le traitement de la presbytie
FR2852252B1 (fr)	2005-07-08	Valve implantable pour le traitement de l'hydrocephalie
FR2801508B1 (fr)	2003-11-14	Utilisation d'inhibiteurs d'hmg coa-reductase pour le traitement de la seborrhee
FR2832429B1 (fr)	2004-01-09	Dispositif porte-pieces perfectionne pour traitement electrolytique
FR2833967B1 (fr)	2004-02-20	Utilisation de bacteries lactiques pour la production d'alpha-cetoglutarate